Compare Corsair Gaming Inc (CRSR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Merck & Co., Inc. — how do they compare? Corsair Gaming Inc trades at $12.94 (market cap $1.39B), while Merck & Co., Inc. trades at $133.12 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 231.5× Corsair Gaming Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals.
| CRSR | MRK | |
|---|---|---|
Market Cap | $1.39B | $321.77B |
Sector | Technology | Health |
52-Week High | $14.35 | $131.84 |
52-Week Low | $4.58 | $77.60 |
Enterprise Value | $1.38B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $12.92, down 5.76% in the last session, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates and raising full-year guidance, while recent acquisitions like Trak Racer and AI product launches aim to drive growth. However, the stock faces valuation concerns with a high P/E ratio of 41.39 and inconsistent profitability, as net income turned positive only in 2026 after previous losses.
The outlook is mixed: improved cash flow and strategic expansions support upside potential, but high valuation and competitive pressures pose risks. Analyst consensus is cautious with a $12.40 price target below the current price, suggesting limited near-term gains despite recent operational improvements.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
